VHL and cancer: These VHL–monobody fusions selectively and efficiently degraded KRAS(G12C) in RASless MEFs (Fig. 4a, Supplementary Fig 10c, e), as well as endogenous RAS in PATU8902 and H23 cancer cell lines (Fig. 4b, c).